GPC2 and neoplasm: In mice, agonist anti-CD40 mAb can augment the anti-tumor efficacy of an anti-GPC2 antibody drug conjugate via macrophage activation [40], and can also facilitate the induction of anti-survivin reactive T cells that kill slightly immunogenic NBLs, likely via antigen-presenting cell activation [41].